文献速递类风湿关节炎

早期类风湿关节炎传统与超声靶向治疗对比:2年内MRI炎症或关节损伤无差异

Conventional versus ultrasound treat to target: no difference in magnetic resonance imaging inflammation or joint damage over 2 years in early rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

230例未使用过改善病情抗风湿药的早期类风湿关节炎患者随机接受超声紧密控制策略(目标DAS<1.6、无肿胀关节且任何关节无能量多普勒信号)或传统策略(目标DAS<1.6且无肿胀关节),两组采用相同药物升级方案。218例有基线及至少一次随访MRI纳入分析,2年内MRI骨髓水肿、滑膜炎和腱鞘炎均改善且两组各时间点无显著差异,2年MRI骨侵蚀进展风险超声组39%与传统组33%相似(RR 1.16,95%CI 0.81-1.66,P=0.40)。

要点

  • 超声靶向治疗未降低早期RA的MRI炎症或结构损伤进展。
  • 2年MRI骨侵蚀进展风险超声组39%与传统组33%无显著差异。
  • 系统使用超声未在早期RA随访中提供额外获益。

核心结论

  • 将超声信息纳入治疗决策未较传统策略减少MRI炎症或结构损伤进展。
  • 系统使用超声在早期RA随访中不提供获益。

研究设计与样本

  • 230例未使用过改善病情抗风湿药的早期RA患者随机分为超声紧密控制策略组或传统策略组。
  • 两组均采用相同改善病情抗风湿药升级策略,优势手MRI在2年内6个时间点按OMERACT RA MRI评分系统评估。
  • 218例有基线及至少一次随访MRI的患者纳入分析。

主要发现

  • MRI骨髓水肿、滑膜炎和腱鞘炎在第一年改善并在第二年维持,两组各时间点无统计学显著差异。
  • 2年MRI骨侵蚀进展风险超声组39%、传统组33%(相对风险1.16,95%CI 0.81-1.66,P=0.40)。

关键数值与推荐

  • 超声紧密控制策略目标为DAS<1.6、无肿胀关节且任何关节无能量多普勒信号。
  • 传统策略目标为DAS<1.6且无肿胀关节。

临床怎么用

  • 早期RA随访中系统使用超声未显示额外获益,不支持常规以超声信息指导治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate whether an ultrasound-guided treat-to-target strategy for early RA would lead to reduced MRI inflammation or less structural damage progression compared with a conventional treat-to-target strategy. METHODS: A total of 230 DMARD-naïve early RA patients were randomized to an ultrasound tight control strategy targeting DAS <1.6, no swollen joints and no power Doppler signal in any joint or a conventional strategy targeting DAS <1.6 and no swollen joints. Patients in both arms were treated according to the same DMARD escalation strategy. MRI of the dominant hand was performed at six time points over 2 years and scored according to the OMERACT RA MRI scoring system. A total of 218 patients had baseline and one or more follow-up MRIs and were included in the analysis. The mean MRI score change from baseline to each follow-up and the 2 year risk for erosive progression were compared between arms. RESULTS: MRI bone marrow oedema, synovitis and tenosynovitis improved over the first year and was sustained during the second year of follow-up, with no statistically significant differences between the ultrasound and the conventional arms at any time point. The 2 year risk for progression of MRI erosions was similar in both treatment arms: ultrasound arm 39%, conventional arm 33% [relative risk 1.16 (95% CI 0.81, 1.66), P = 0.40]. CONCLUSION: Incorporating ultrasound information in treatment decisions did not lead to reduced MRI inflammation or less structural damage compared with a conventional treatment strategy. The findings support that systematic use of ultrasound does not provide a benefit in the follow-up of patients with early RA. TRIAL REGISTRATION NUMBER: Clinicaltrials.gov, http://clinicaltrials.gov, NCT01205854.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Sundin U, Aga AB, Skare Ø, et al. Conventional versus ultrasound treat to target: no difference in magnetic resonance imaging inflammation or joint damage over 2 years in early rheumatoid arthritis. Rheumatology (Oxford). 2020. PMID: 31999341. doi:10.1093/rheumatology/kez674

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。